Last viewed: PRGO

Prices are updated after-hours

PRGO 2021 - 03 - 10

Perrigo Company

PRGO | $30.57 0.26% 100K

|

Health Technology

(0.0% 1d) (-1.7% 1m) (-15.8% 1y) (0.0% 2d) (1.4% 3d) (-1.0% 7d) (-21.39% volume)
Earnings Calendar:
Market Cap: $ 4,142,722,255
http://www.perrigo.com
Sec Filling | Patents | 11200 employees

(IE) Perrigo Co. Plc engages in providing over-the-counter (OTC) self-care and wellness solutions. Its solutions enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. The firm operates through three segments: Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals. The Consumer Self-Care Americas segment comprises the store brand consumer self-care business in the U.S., Mexico and Canada. The Consumer Self-Care International segment includes the branded consumer self-care business in Europe, along with consumer-focused businesses in the U.K. and Australia. The Prescription Pharmaceuticals commercializes and manufactures generic prescription products in the U.S. and diagnostic products in Israel. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

israel brands diagnostics

Drugs

ESTRADIOL VALERATE (ESTRADIOL VALERATE)

add to watch list Paper trade email alert is off

Press-releases

FDA Rejects Abeona’s Gene Therapy, Approves ImmunityBio’s Bladder Cancer Treatment
Published: 2024-04-23 (Crawled : 13:30) - biospace.com/
PRGO | $30.57 0.26% 100K

|

Health Technology

| 1.43% | O: 0.13% H: 1.89% C: 1.3%
JNJ | News | $147.885 -1.12% 1.5M

|

Health Technology

| 0.89% | O: 0.89% H: 0.0% C: 0.0%
ABT | News | $105.9 -1.57% 1.3M

|

Health Technology

| 0.49% | O: 0.56% H: 0.41% C: -0.07%
SNY | News | $47.1 -1.24% 260K

|

Health Technology

| 1.7% | O: 1.7% H: 0.0% C: 0.0%
fda bladder cancer treatment

Genentech’s ALK Inhibitor First Adjuvant Treatment for ALK-Positive, Early NSCLC
Published: 2024-04-19 (Crawled : 15:00) - biospace.com/
PRGO | $30.57 0.26% 100K

|

Health Technology

| 1.5% | O: -0.4% H: 3.01% C: 2.94%
JNJ | News | $147.885 -1.12% 1.5M

|

Health Technology

| 3.25% | O: 0.83% H: 1.35% C: 1.2%
ABT | News | $105.9 -1.57% 1.3M

|

Health Technology

| 1.12% | O: -0.75% H: 0.0% C: 0.0%
SNY | News | $47.1 -1.24% 260K

|

Health Technology

| 3.41% | O: 0.82% H: 0.0% C: 0.0%
first treatment for

AstraZeneca Wins Label Expansion for Severe Asthma Drug in Younger Kids
Published: 2024-04-12 (Crawled : 14:30) - biospace.com/
PRGO | $30.57 0.26% 100K

|

Health Technology

| -2.53% | O: -0.13% H: 0.0% C: -2.94%
JNJ | News | $147.885 -1.12% 1.5M

|

Health Technology

| -0.69% | O: -1.65% H: 0.0% C: 0.0%
ABT | News | $105.9 -1.57% 1.3M

|

Health Technology

| -3.46% | O: -1.06% H: 0.21% C: -1.05%
SNY | News | $47.1 -1.24% 260K

|

Health Technology

| -0.73% | O: -3.02% H: 0.0% C: 0.0%
drug label astrazeneca expansion for kids

Busy Weekend Sees Tumor-Agnostic Win for Enhertu, Another Rejection for Supernus
Published: 2024-04-08 (Crawled : 15:00) - biospace.com/
SNYNF | News | $94.25 480

|

Health Technology

| 1.68% | O: 2.24% H: 0.0% C: -0.8%
PRGO | $30.57 0.26% 100K

|

Health Technology

| -2.9% | O: 0.96% H: 1.17% C: 0.16%
JNJ | News | $147.885 -1.12% 1.5M

|

Health Technology

| -1.88% | O: -0.48% H: 0.0% C: 0.0%
ABT | News | $105.9 -1.57% 1.3M

|

Health Technology

| -3.25% | O: 0.09% H: 0.16% C: -0.7%
SNY | News | $47.1 -1.24% 260K

|

Health Technology

| 0.29% | O: 0.84% H: 0.0% C: 0.0%
for

FDA Greenlights New Antibiotic for SAB, Pneumonia
Published: 2024-04-05 (Crawled : 13:30) - biospace.com/
SNYNF | News | $94.25 480

|

Health Technology

| -1.93% | O: -1.77% H: 0.0% C: -1.81%
PRGO | $30.57 0.26% 100K

|

Health Technology

| -3.05% | O: -0.22% H: 0.8% C: 0.06%
JNJ | News | $147.885 -1.12% 1.5M

|

Health Technology

| -3.69% | O: -1.84% H: 0.0% C: 0.0%
ABT | News | $105.9 -1.57% 1.3M

|

Health Technology

| -2.29% | O: -0.37% H: 1.42% C: 1.37%
SNY | News | $47.1 -1.24% 260K

|

Health Technology

| -3.16% | O: -3.44% H: 0.0% C: 0.0%
fda for

FDA Approves Vanda Schizophrenia Drug for Bipolar I Disorder
Published: 2024-04-03 (Crawled : 13:30) - biospace.com/
PRGO | $30.57 0.26% 100K

|

Health Technology

| -2.65% | O: -0.29% H: 1.34% C: -0.64%
JNJ | News | $147.885 -1.12% 1.5M

|

Health Technology

| -5.12% | O: 0.02% H: 0.0% C: 0.0%
ABT | News | $105.9 -1.57% 1.3M

|

Health Technology

| -3.95% | O: 0.11% H: 0.37% C: -0.77%
SNY | News | $47.1 -1.24% 260K

|

Health Technology

| -1.34% | O: 0.69% H: 0.0% C: 0.0%
fda drug schizophrenia

AstraZeneca Kicks Off April With New PNH Approval
Published: 2024-04-02 (Crawled : 13:30) - biospace.com/
PRGO | $30.57 0.26% 100K

|

Health Technology

| -5.05% | O: -1.09% H: 0.13% C: -1.39%
JNJ | News | $147.885 -1.12% 1.5M

|

Health Technology

| -5.15% | O: -0.77% H: 0.8% C: 0.74%
ABT | News | $105.9 -1.57% 1.3M

|

Health Technology

| -4.01% | O: -0.18% H: 0.47% C: 0.12%
SNY | News | $47.1 -1.24% 260K

|

Health Technology

| -3.5% | O: -1.14% H: 0.02% C: -1.06%
approval astrazeneca

Global Immune Health Supplements Outlook Report 2023-2029: Vendors Focus on Advancements and Quality, Creating Competition by Offering Innovative Solutions
Published: 2024-03-29 (Crawled : 11:00) - prnewswire.com
BRBR | $55.43 -1.32% 120K

|

Health Technology

| Email alert Add to watchlist
PRGO | $30.57 0.26% 100K

|

Health Technology

| Email alert Add to watchlist
MEDE | $0.51 0% 500

|

| Email alert Add to watchlist
report health offering global solutions

FDA Approves Treatments for Anemia in Chronic Kidney Disease, Hepatitis
Published: 2024-03-29 (Crawled : 19:00) - biospace.com/
SNY | News | $47.1 -1.24% 260K

|

Health Technology

| Email alert Add to watchlist
ABT | News | $105.9 -1.57% 1.3M

|

Health Technology

| Email alert Add to watchlist
JNJ | News | $147.885 -1.12% 1.5M

|

Health Technology

| Email alert Add to watchlist
PRGO | $30.57 0.26% 100K

|

Health Technology

| Email alert Add to watchlist
SNYNF | News | $94.25 480

|

Health Technology

| Email alert Add to watchlist
fda hepatitis kidney anemia

FDA Approves New Treatments for Two Rare Diseases
Published: 2024-03-27 (Crawled : 13:30) - biospace.com/
SNYNF | News | $94.25 480

|

Health Technology

| -5.71% | O: -0.26% H: 0.0% C: 0.0%
PRGO | $30.57 0.26% 100K

|

Health Technology

| -1.01% | O: 0.84% H: 1.48% C: 1.29%
JNJ | News | $147.885 -1.12% 1.5M

|

Health Technology

| -3.84% | O: 0.3% H: 0.0% C: 0.0%
ABT | News | $105.9 -1.57% 1.3M

|

Health Technology

| -2.58% | O: 1.48% H: 0.0% C: 0.0%
SNY | News | $47.1 -1.24% 260K

|

Health Technology

| -4.35% | O: 1.06% H: 0.0% C: 0.0%
fda rare

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001585364-24-000063	4	2024-04-09	2024-04-05	Buy	A	13376	13376
0001585364-24-000062	4	2024-04-09	2024-04-05	Buy	A	17197	17197
0001585364-24-000061	4	2024-04-09	2024-04-05	Buy	A	6210	6210
0001585364-24-000060	4	2024-04-09	2024-04-05	Buy	A	53503	53503
0001585364-24-000059	4	2024-04-09	2024-04-05	Buy	A	17197	17197

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

63%

37%

Top 10 Gainers

CSSE 4 | $0.3686 142.02% 76M

|

Consumer Services

CZOO | $11.685 134.17% 7.6M

|

BOF | $1.93 64.96% 55M

|

AMST | $3.14 57.0% 59M

|

Technology Services

TROO | $1.57 44.04% 2.8M

|

RILY | $30.87 42.13% 7.8M

|

LICN | $0.76 35.71% 6.2M

|

WHLM | $6.61 30.12% 400K

|

Commercial Services

MULN | News | $3.53 29.3% 4.8M

|

RBBN 4 | $3.26 26.85% 1.2M

|

Electronic Technology

Last 48 Hours Insiders Buying

MEGI | $11.97 -0.08% 42K

|

| 00:30
CTRN P 29000 | $22.445 0.97% 16K

|

| 22:00
CONN | $3.7 12K

|

| 21:30
TGEN P 6000 | $0.685 6.6K

|

| 18:30
CMTV P 700 | $16.59 1K

|

Finance and Insurance

| 18:30
FNB | $13.615 -0.11% 110K

|

| 17:30
RMCF | $3.54 410

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar